期刊
JOURNAL OF PERSONALIZED MEDICINE
卷 10, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/jpm10040225
关键词
biomarkers; renal cell carcinoma; clear cell; VEGF; immunotherapy; PD-L1; immune checkpoint inhibitors; immune checkpoint blockade; tyrosine-kinase inhibitors
The treatment of metastatic renal cell carcinoma has evolved quickly over the last few years from a disease managed primarily with sequential oral tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) pathway, to now with a combination of therapies incorporating immune checkpoint blockade (ICB). Patient outcomes have improved with these innovations, however, controversy persists regarding optimal sequence and patient selection amongst the available combinations. Ideally, predictive biomarkers would aid in guiding treatment decisions and personalizing care. However, clinically-actionable biomarkers have remained elusive. We aim to review the available evidence regarding biomarkers for both TKIs and ICB and will present where the field may be headed in the years to come.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据